Yi Fang

InventisBio is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative small-molecule therapeutics for oncology and metabolic diseases. The company has successfully commercialized two products in China: Rezivertinib (BPI-7711), a third-generation EGFR inhibitor for non-small cell lung cancer (NSCLC), and Garsorasib (D-1553), a KRAS G12C inhibitor. Its advanced pipeline includes Taragarestrant (D-0502), an oral selective estrogen receptor degrader (SERD) in Phase 3 for breast cancer, and Darbinurad (D-0120), a URAT1 inhibitor in Phase 3 for gout. InventisBio is listed on the Shanghai Stock Exchange STAR Market and maintains strategic partnerships with industry leaders such as Betta Pharma and Sino Biopharmaceutical. The company operates an integrated R&D platform with facilities in Shanghai, Beijing, and New Jersey, focusing on "first-in-class" and "best-in-class" treatments to address significant unmet medical needs.